ERBB2 and gastric cancer: In comparison with using chemotherapy alone, ToGA trial showed that adding trastuzumab (Herceptin, Roche), an effective anti-HER2 humanized monoclonal antibody, in traditional chemotherapy could noticeably increase progression-free survival and overall survival in HER2-positive GC [3].